Fleury S.A. (FLRY3)
B3 Stock Exchange · Brazil · prices in BRL · close of 27 Oct 2026
Key indicators
| Last close | BRL 22.92 |
|---|---|
| 52-week range | 13.90 – 28.65 |
| Return, 1 month / 3 months | +5.4% / +41.7% |
| Return, 1 year / 3 years | +68.1% / +84.5% |
| Trend | Uptrend |
| RSI (14) | 41 |
| Volatility (1 year) | 38.4% |
| Worst drawdown (1 year) | -21.6% |
| Average daily value traded | 119.51M BRL |
| Dividend yield | 5.1% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Fleury S.A. is a Brazilian healthcare company that provides medical diagnostic services. It operates clinical laboratories that perform blood and other specimen tests, and it runs diagnostic imaging centres offering services such as ultrasound and magnetic resonance scans. Its customers are patients, physicians and health insurers, and it serves individuals and companies through a network of units concentrated in Brazil's urban centres, with its headquarters in Sao Paulo.
Fleury S.A. trades under the code FLRY3 on the B3 Stock Exchange in Brazil, with its price quoted in Brazilian reais (BRL). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Fleury S.A. (FLRY3) trades on the B3 Stock Exchange in Brazil. It last closed at BRL 22.92 on 27 October 2026.
Its price-based Market X-Ray is 77 out of 100 (a strong price profile), ranking 37 of 1,455 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 68.1% and over the last three months it rose 41.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on B3 Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 76 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 30.8% | ||
| From 52-week high | -18.7% | ||
| Momentum | 92 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 41.7% | ||
| 6-month return | 46.4% | ||
| 12-month return, skipping the last month | 59.4% | ||
| Stability (higher is calmer) | 60 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 38.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -21.6% | ||
| Liquidity | 96 · Strong | Trades actively. | |
| Average daily value traded | 119.51M BRL | ||
| Zero-volume days | 0.0% | ||
| Income | 60 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 5.1% | ||
| Years with dividends | 6 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | −18.7% |
|---|---|
| 1 month | +5.4% |
| 3 months | +41.7% |
| 6 months | +46.4% |
| 1 year | +68.1% |
| 3 years | +84.5% |
| 5 years | +69.2% |
Signals
| 50-day / 200-day average | 22.39 / 17.52 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.21 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 11 Aug 2026 | BRL 0.4007 |
| 2 Dec 2025 | BRL 0.7688 |
| 12 Aug 2025 | BRL 0.3101 |
| 6 Mar 2025 | BRL 0.4661 |
| 13 Dec 2024 | BRL 0.2139 |
| 14 Aug 2024 | BRL 0.3374 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on B3 Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.